Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
Lung cancer is the second tumor in frequency for both sex, but is well established as the leading cause of cancer deaths worldwide. Most patients are diagnosed in a advanced stage of disease and treated with conventional chemotherapy providing symptomatic relief with only modest improvement in survival. New data revealed that in the last 10 years empirical treatment was substituted for targeted therapy. Specifically for lung cancer a predictive biomarker for response to treatment is the mutation of the EGFR receptor (epidermal growth factor) which is present in about 30% of patients. Several phase III studies have shown a benefit in progression-free survival and overall survival for tyrosine kinase inhibitors such as erlotinib and gefitinib in second line treatment. The objective of this study is to report the epidemiological monitoring of lung non-small cell cancer at the Oncology Service of Hospital Carlos Andrade Marin and the experience obtained with the use of erlotinib as a second-line treatment between 2010 to 2013.
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.